Source comparison
CJC-1295 Ipamorelin Stack vs Single-Agent Protocols
CJC-1295 alone GHRH receptor agonist. Extends GH pulse amplitude 200-300mcg 2-3x weekly 3-5% body fat reduction Minimal change Effective for sustained baseline GH elevation but lacks the sharp pulsatile peaks that maximise lipolysis. Better for anti-aging than
This comparison does not assign a generated winner or score.
- CJC-1295 alone
- GHRH receptor agonist. Extends GH pulse amplitude
- 200-300mcg 2-3x weekly
- 3-5% body fat reduction
- Minimal change
- Effective for sustained baseline GH elevation but lacks the sharp pulsatile peaks that maximise lipolysis. Better for anti-aging than aggressive fat loss
- Ipamorelin alone
- Ghrelin receptor agonist. Increases GH pulse frequency
- 200-300mcg 1-2x daily
- 4-6% body fat reduction
- +0.5-1.5kg
- Produces potent short-duration pulses but requires frequent dosing to maintain effect. Most cost-effective single agent for fat loss
- CJC-1295 + Ipamorelin stack
- Dual-pathway activation. GHRH + ghrelin receptor synergy
- 200mcg each nightly or split dosing
- 6-9% body fat reduction
- +1.5-3kg
- Synergistic effect produces 15-20% greater fat oxidation than either compound alone while preserving muscle. Gold standard for body recomposition but requires stricter injection schedule
- Modified GRF (1-29) + Ipamorelin
- Short-acting GHRH analog + ghrelin agonist
- 100mcg each 2-3x daily
- 5-8% body fat reduction
- +1-2.5kg
- Lower cost alternative to CJC-1295 stack with similar mechanism but requires more frequent dosing. Preferred for those unable to use DAC-modified peptides
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 10-25mg daily oral
- +2-4kg
- Convenient oral administration but causes significant water retention and appetite stimulation that complicates caloric deficit. Lean mass gains are partially glycogen and fluid